Our AHSC cardiovascular programme is focussed on developing innovative approaches to prevent heart disease and creating new medicines and devices that will benefit of patients with or at risk of heart disease or stroke.

Our AHSN cardiovascular programme compliments this by working to improve the cardiac health of our patient population through partnerships that make a real difference in population and place-based care.

Cardiovascular disease programme (AHSN)

Two thirds of premature deaths in the UCLPartners population of around six million people are caused by cancer or heart disease. The objective of the CVD programme is to support the our partners transformation towards place based systems of care that will deliver improved population health and greater sustainability by focusing on cardiovascular prevention and new models of care.

Our CVD work currently focusses on Atrial Fibrillation (AF). Read more about our AF work.

Programme leadership

Dr John Robson, Primary Care Lead and Sotiris Anotniou, Pharmacy Lead.

Cardiovascular programme (AHSC)

Our cardiovascular programme aims to achieve maximum global, national and regional impact for the benefit of patients with or at risk of heart disease or stroke.

The cardiovascular programme draws on a multitude of skills and resources that exist within the partnership. Specifically it brings together the research strengths of UCL and Queen Mary University London (QMUL); the translational infrastructure of University College London Hospital (UCLH), Moorfields Eye Hospital NHS Foundation Trust, Great Ormond Street Hospital for Children NHS Foundation Trust and Barts Health NHS Trust; and the clinical expertise of three specialist cardiac hospitals (UCLH’s Heart Hospital, Barts Heart Centre at St Bartholomew’s Hospital and the Royal Free Hospital).

The cardiovascular programme has two workstreams. You can read more about these below.

Joint Translational Cardiovascular Institute (JTCI)

The JTCI will bring together the world-leading faculty from the William Harvey Research Institute at QMUL with pioneering clinician-scientists from the UCL Institute of Cardiovascular Science. The aim of this institute is to deliver an internationally leading translational academic strategy. This strategy will accelerate diagnostic and therapeutic innovation originating from the universities into cardiovascular clinical care for the benefit of patients.

Progress to date

A site has been identified for a devices facility and a bid of £10.2 million has been submitted to support this, match-funded by Barts Charity.

Barts Heart Centre

This state-of-the art heart centre brings together specialist cardiovascular services with many co-located academics and clinical teams from three hospitals (the London Chest Hospital, UCLH’s Heart Hospital and Barts Heart Centre at St Bartholomew’s Hospital). The centre provides a focussed translational research environment and has over 80,000 patient episodes per year.

Progress to date

Barts Heart Centre at St Bartholomew’s Hospital was opened in May 2015. The National Institute for Cardiovascular Outcomes Research (NICOR) has also relocated to the new campus. NICOR helps the NHS, the government and regulatory bodies improve quality of care by checking that the care received by heart disease patients meets good practice standards. Being located on the Barts Heart Centre campus ensures cardiovascular clinicians have greater access to data.


Programme leadership

Professor Steffen Petersen, Professor of Cardiovascular Medicine, Queen Mary University of London